GLP-2 analogue, resistant to peptidase degradation. Enhanced biological activity relative to native GLP-2
See full description
Jeppesen (2012) Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome. Ther. Adv. Gastroenterol. 5(3) 159 PMID: 22570676
Schwartz et al (2016) Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome. Clin.Transl. Gastroenterol. 7(2) e142 PMID: 26844839
Teduglutide is a GLP-2 analogue, in which the alanine at position 2 has been substituted with glycine making the peptide resistant to degradation by dipeptidyl peptidase-4 (DPP-4). Teduglutide therefore has a longer half-life than GLP-2 (2-3 hours for teduglutide vs 7 min for GLP-2). Teduglutide has high bioavailability after subcutaneous administration, suggesting that teduglutide has enhanced biological activity, relative to native GLP-2.
GLP-2 is a gut hormone produced in the enteroendocrine L cells of gastrointestinal tract by the cleavage of the 160-amino-acid proglucagon molecule. GLP-2 is secreted following the ingestion of food and carries out its activities via the GLP-2 G-protein coupled receptors (GLP-2Rs). GLP-2 has a range of roles within the cell, including: anti-inflammatory effects; promoting the expansion of the intestinal mucosa; stimulating intestinal blood flow; inhibiting gastric acid secretion and gastric emptying; increasing intestinal barrier function and enhancing nutrient and fluid absorption
Search our datasheets by catalogue number, peptide sequence or name.
Discover more about how we can support you and our products.
Find answers to common queries about our products and company.
Cambridge Research Biochemicals 17-18 Belasis Court, Belasis Hall Technology Park Billingham TS23 4AZ
t +44 01642 567 183